HIV 101: Optimization of Management of People Who Are Newly Diagnosed With HIV

Assessment of Needs

A firm grasp of the basics of clinical care for patients with HIV is essential for practitioners in Ryan White HIV/AIDS-funded clinics and programs who are new to HIV care. In this webinar, experts in the field described the core principles of HIV management, including primary care for people who are newly diagnosed with HIV, initiating antiretroviral therapy, and management of HIV in those with common opportunistic infections, those with HIV-associated dermatologic manifestations, and in those who are pregnant. This webinar is also useful to experienced clinicians who seek a review of these core principles.

Note: This year’s webinar will not cover HIV pathogenesis or epidemiology. Attendees are encouraged to review these foundational topics in advance by viewing last year’s webinar, HIV 101: Foundations of Management of People Who Are Newly Diagnosed With HIV.

https://www.iasusa.org/courses/on-demand-webinar-2025-saag-chu-gulick/

Learning Objectives

On completion of this activity, learners will be able to:

• Describe the initial evaluation and first-line antiretroviral therapy (ART) for adults with newly diagnosed, uncomplicated HIV

• Incorporate principles of individualized ART selection for patients with common comorbidities and special clinical considerations, including kidney disease and potential drug resistance

• Recognize common opportunistic infections, HIV-associated dermatologic manifestations, and non-ART-related complications of HIV

Initial Evaluation and Preventive Care for Individuals Newly Diagnosed With HIV
Darcy A. Wooten, MD
Learning Objectives

On completion of this activity, learners will be able to:

• Describe the recommended initial evaluation of a newly diagnosed person with HIV (PWH), including baseline laboratory testing and assessment of co-occurring conditions
• Describe an appropriate vaccination and preventive care plan for PWH based on immune status, age, risk factors, and current guidelines
• List preventive screening recommendations for PWH, including cardiovascular risk assessment and cancer screening

HIV Treatment Essentials: Principles of Patient-Specific Antiretroviral Regimens
Rajesh T. Gandhi, MD
Learning Objectives

On completion of this activity, learners will be able to:

• List appropriate first-line antiretroviral (ARV) regimens for adults with newly diagnosed, uncomplicated HIV
• Describe common drug-drug interactions with first-line ARV regimens
• Describe the principles of individualized ART selection for patients with common co-occurring conditions and special clinical considerations, such as kidney disease

Clinical Cases: Management of Special Populations and Complications
Michael S. Saag, MD
Learning Objectives

On completion of this activity, learners will be able to:

• Describe evidence-based approaches to the diagnosis and management of common opportunistic infections through clinical case discussions
• List management strategies for people with HIV in special clinical circumstances, such as those who are pregnant and those who have undergone solid organ transplantation
• Describe common HIV-associated dermatologic manifestations and non-antiretroviral therapy–related complications of HIV

Registration

Who Should Attend

This program is designed for clinical decision-makers in Ryan White HIV/AIDS Program (RWHAP)-funded clinics and programs who are new to HIV care and those practitioners who are interested in a review. It is also relevant for registered nurses, pharmacists, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on Monday, October 19, 2026, 12:30 PM (PT).

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenter/Planner

Dr Saag reported no relevant financial relationships with ineligible companies. (Updated August 18, 2026)

Presenters

Dr Wooten reported no relevant financial relationships with ineligible companies. (Updated August 7, 2026)
Dr Gandhi reported no relevant financial relationships with ineligible companies. (Updated May 16, 2026)

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/